Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cipla
Teva
Moodys
Julphar
QuintilesIMS
Healthtrust
Citi
McKinsey
Farmers Insurance

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,023,790

« Back to Dashboard

Which drugs does patent 9,023,790 protect, and when does it expire?

Patent 9,023,790 protects NOXAFIL and is included in one NDA.

This patent has fourteen patent family members in ten countries.
Summary for Patent: 9,023,790
Title:Posaconazole intravenous solution formulations stabilized by substituted .beta.-cyclodextrin
Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified .beta.-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.
Inventor(s): Heimbecher; Susan K. (Morris Plains, NJ), Monteith; David (Pittstown, NJ), Pipkin; James D. (Lawrence, KS)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/704,145
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Device;

Drugs Protected by US Patent 9,023,790

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme NOXAFIL posaconazole SOLUTION;IV (INFUSION) 205596-001 Mar 13, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,023,790

PCT Information
PCT FiledJune 24, 2011PCT Application Number:PCT/US2011/041715
PCT Publication Date:January 12, 2012PCT Publication Number: WO2012/005973

Non-Orange Book US Patents Family Members for Patent 9,023,790

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,358,297 Posaconazole intravenous solution formulations stabilized by substituted .beta.-cyclodextrin ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,023,790

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 338685 ➤ Subscribe
Mexico 2012015168 ➤ Subscribe
South Korea 20130114603 ➤ Subscribe
Japan 6008849 ➤ Subscribe
Japan 2013535422 ➤ Subscribe
European Patent Office 2588116 ➤ Subscribe
China 107049935 ➤ Subscribe
China 102958528 ➤ Subscribe
Canada 2802929 ➤ Subscribe
Brazil 112012033077 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Argus Health
Chubb
Medtronic
Merck
UBS
McKinsey
Colorcon
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot